Abstract
Health technology assessments (HTAs) of vaccines typically focus on the direct health benefits to individuals and healthcare systems. COVID-19 highlighted the widespread societal impact of infectious diseases and the value of vaccines in averting adverse clinical consequences and in maintaining or resuming social and economic activities. Using COVID-19 as a case study, this research work aimed to set forth a conceptual framework capturing the broader value elements of vaccines and to identify appropriate methods to quantify value elements not routinely considered in HTAs. A two-step approach was adopted combining a targeted literature review and three rounds of expert elicitation based on a modified Delphi method, leading to a conceptual framework of 30 value elements related to broader health effects, societal and economic impact, public finances, and uncertainty value. When applying the framework to COVID-19 vaccines in post-pandemic settings, 13 value elements were consensually rated highly important by the experts for consideration in HTAs. The experts reviewed over 10 methods that could be leveraged to quantify broader value elements and provided technical forward-looking recommendations. Limitations of the framework and the identified methods were discussed. This study supplements on-going efforts aimed towards a broader recognition of the full societal value of vaccines.
Competing Interest Statement
Conflicts of Interest: MDF, DM, JY are employees of Pfizer and may hold stock or stock options of Pfizer. KM, JR and GS are employees of Evidera, which received financial support from Pfizer, Inc. in connection with the study and the development of this manuscript. Shailja Vaghela is an employee of HealthEcon Consulting, Inc. and an external consultant for Pfizer who has received consulting fees from Pfizer in connection with the development of this manuscript. L.S. is an employee of the Office of Health Economics, a registered charity and Independent Research Organisation which receives funding from a variety of private and public sector sources. D.E.B. consults for Data for Decisions, LLC on research contracts with Pfizer. He has also received compensation from Pfizer, Sanofi, GSK, and Merck for providing consulting services and for speaking and participating in meetings, executive education programs, and advisory boards. M.D. has consulted on several economic evaluations of vaccines for different manufacturers K.H. received personal fees from GSK and WHO for research unrelated to this work J.P.S. is partner and head of Health Analytics at Lane Clark & Peacock LLP, Chair of the Royal So-ciety for Public Health and reports personal fees from Novo Nordisk A/S and Pfizer Ltd outside of the submitted work. D.S. Paid consultancies for Pfizer, GSK, Sanofi, AstraZeneca, Clover, Moderna, MSD, BioNTech, Se-qirus. A.T. is an employee of the Office of Health Economics, a registered charity and Independent Research Organisation which receives funding from a variety of private and public sector sources. The experts were compensated for their time during the expert discussions.
Funding Statement
This study was funded by Pfizer Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Aggregate data generated or analysed during this study are available from the corresponding author, upon review.
